AOM reports Phase III Foznol data

AnorMed (TSE:AOM) said that in a U.S. Phase III trial of 163 end-stage renal disease (ESRD) patients, 59% of patients given AOM's Foznol lanthanum carbonate had a clinically acceptable blood phosphate...